BiotechTube

ChAdOx1-HPV + MVA-HPV + Placebo

Phase 1/2Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

HPV Infection

Conditions

HPV Infection, CIN1

Trial Timeline

Mar 16, 2021 → Jan 16, 2024

NCT ID
NCT04607850

About ChAdOx1-HPV + MVA-HPV + Placebo

ChAdOx1-HPV + MVA-HPV + Placebo is a phase 1/2 stage product being developed by Barinthus Biotherapeutics for HPV Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT04607850. Target conditions include HPV Infection, CIN1.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT04607850Phase 1/2Completed

Competing Products

20 competing products in HPV Infection

See all competitors
ProductCompanyStageHype Score
BSG005Alkem LaboratoriesPhase 1/2
41
Zotatifin + PlaceboeFFECTOR TherapeuticsPhase 1
25
AAVLP-HPV + Placebo2A PharmaPhase 1
25
CT-P59CelltrionPhase 1
33
CT-P63 + PlaceboCelltrionPhase 1
33
CT-P59 + CT-P59 + Placebo + CT-P59 + PlaceboCelltrionPhase 2/3
65
CT-P59 + PlaceboCelltrionPhase 1
33
SOF + COPEChugai PharmaceuticalPre-clinical
23
Edoxaban Tablets + Colchicine TabletsDaiichi SankyoPhase 3
77
VN-0200 + PlaceboDaiichi SankyoPhase 1
33
VN-0200Daiichi SankyoPhase 2
52
Levofloxacin + Solifenacin succinate + Placebo (for Solifenacin succinate)Astellas PharmaApproved
85
MicafunginAstellas PharmaPhase 1
33
MicafunginAstellas PharmaPre-clinical
23
amphotericin B liposomal (Ambisome)Astellas PharmaApproved
85
Parenteral micafungin application + Other parenteral antifungal drugsAstellas PharmaPre-clinical
23
Fidaxomicin + Treatment for CDI other than fidaxomicin TypeAstellas PharmaPre-clinical
23
Isavuconazonium sulfate + Voriconazole + PosaconazoleAstellas PharmaPre-clinical
23
Ciclosporin and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to EverolimusAstellas PharmaApproved
85
DOR/ISLMerckPhase 2
52

Other Products from Barinthus Biotherapeutics

MVA-NP+M1 + SalinePhase 2
44
ChAdOx1-HBV + MVA-HBV + NivolumabPhase 2
44
Seasonal influenza vaccine + MVA-NP+M1 + Sodium chloridePhase 2
44
MVA-NP+M1 + Saline + H3N2 (A/Belgium/2417/2015)Phase 2
44
ChAdOx1-MVA 5T4 vaccine + Nivolumab Infusion [Opdivo]Phase 1/2
33